Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective. [electronic resource]
Producer: 20200617Description: 1243-1252 p. digitalISSN:- 1941-837X
- Antineoplastic Agents -- administration & dosage
- Chemotherapy, Adjuvant
- Cost-Benefit Analysis
- Disease-Free Survival
- Drug Therapy, Combination
- Health Expenditures -- statistics & numerical data
- Humans
- Imidazoles -- administration & dosage
- Lymphatic Metastasis
- Melanoma -- drug therapy
- Models, Econometric
- Neoplasm Staging
- Oximes -- administration & dosage
- Proto-Oncogene Proteins B-raf -- genetics
- Pyridones -- administration & dosage
- Pyrimidinones -- administration & dosage
- Quality-Adjusted Life Years
- Skin Neoplasms -- drug therapy
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.